Combining PI with the pan B-cell-directed Bruton tyrosine kinase inhibitor ibrutinib appears a natural option for future improved treatment of multiple myeloma (MM) and B-cell lymphomas. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.